Oncolytics Biotech is focused on advancing cancer treatment through its innovative immunotherapy, pelareorep. This unique therapy is designed to activate the immune system and enhance its ability to combat tumors. Delivered intravenously, pelareorep distinguishes itself from other immunotherapies that require direct tumor injection, allowing for systemic activity. The therapy selectively replicates within cancer cells, generating both innate and adaptive immune responses that can improve the effectiveness of existing treatments, such as chemotherapy and immune checkpoint inhibitors. Clinical data from patients with HR+/HER2- metastatic breast cancer and pancreatic cancer indicate that pelareorep may extend survival times and reduce tumor burden when used in conjunction with standard treatment regimens.

Oncolytics Biotech is committed to exploring the broad potential of pelareorep across various cancer indications. The company collaborates with multiple academic and pharmaceutical partners to investigate its capabilities further. The unique mechanism of action of pelareorep not only positions it as a promising standalone treatment but also as a complementary agent to enhance the efficacy of other viral-based immunotherapies. Through ongoing clinical trials and research, Oncolytics aims to provide patients with more quality time and improved outcomes in their cancer journey.

Canada

Oncolytics Biotech Inc. is developing pelareorep, a safe and well-tolerated intravenously delivered immuno-oncolytic virus (IOV) that targets cancer through a unique mechanism of action with two components, selective tumor lysis and activation of the innate and adaptive immune systems, creating an inflamed phenotype to treat a variety of solid tumors and hematological malignancies.


Cancer

Digestive System Diseases

Hematologic Diseases

Urogenital Diseases

Oncolytics Biotech

Breast cancer

<p class="font_7">Pelareorep&nbsp;is&nbsp;a&nbsp;non-pathogenic,&nbsp;proprietary&nbsp;isolate&nbsp;of&nbsp;the&nbsp;unmodified&nbsp;reovirus:&nbsp;a&nbsp;first-in-class&nbsp;intravenously delivered immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses to treat a variety of cancers and has been demonstrated to be able to escape neutralizing antibodies found in&nbsp;patients.</p>

Pelareorep + paclitaxel + avelumab (Bavencio®) 

Pancreatic cancer

Pelareorep + gemcitabine, nab-paclitaxel, atezolizumab

Triple-negative breast cancer

<p class="font_7">Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus: a first-in-class intravenously delivered immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses to treat a variety of cancers and has been demonstrated to be able to escape neutralizing antibodies found in patients.</p>

Oncolytics Biotech

Company Details